

## Supporting Information For

### A Cascade Reaction of Cinnamyl Azides with Acrylates Directly Generates Tetrahydro-Pyrrolo-Pyrazole Heterocycles

Angela S. Carlson<sup>‡</sup>, En-Chih Liu<sup>‡</sup>, and Joseph J. Topczewski\*

Department of Chemistry, University of Minnesota Twin Cities, Minneapolis Minnesota 55455,  
United States  
jtopczew@umn.edu


#### Table of Contents

|                                    |            |
|------------------------------------|------------|
| <b>Reaction Optimization .....</b> | <b>S2</b>  |
| <b>X-ray Data .....</b>            | <b>S5</b>  |
| <b>HPLC data.....</b>              | <b>S8</b>  |
| <b>References.....</b>             | <b>S10</b> |
| <b>NMR Spectra Images .....</b>    | <b>S11</b> |

## Reaction Optimization

**Procedure for screening reaction concentration (Table S1)** - A stock solution of azide **1b** (150 mg, 0.942 mmol) and naphthalene (29.9 mg, 0.234 mmol, internal standard) was prepared in C<sub>6</sub>H<sub>6</sub> (1.3 mL). Individual 4 mL vials were charged with 0.25 mL portions of this solution and diluted with C<sub>6</sub>H<sub>6</sub> (0, 0.25, 0.75, and 1.75 mL) to the appropriate concentration. Methyl acrylate (20 μL) and TEA (80 μL) were added and the vials were sealed under air and heated to 70 °C. After 65 h, the reactions were concentrated under reduced pressure and analyzed by <sup>1</sup>H NMR. All other screens were performed via an analogous procedure varying the specified conditions.


**Table S1. Concentration screen.**



| entry | concentration (M) | 1a (%) <sup>a</sup> | 5a (%) <sup>a</sup> | 4a (%) <sup>a</sup> |
|-------|-------------------|---------------------|---------------------|---------------------|
| 1     | 0.8               | 8                   | 16                  | 30                  |
| 2     | 0.4               | 4                   | 29                  | 32                  |
| 3     | 0.2               | 10                  | 49                  | 20                  |
| 4     | 0.1               | 22                  | 50                  | 7                   |

<sup>a</sup>Conversion and yield were determined by <sup>1</sup>H NMR.

**Table S2. Temperature screen.**



| entry | temperature (°C) | 5a (%) <sup>a</sup> |
|-------|------------------|---------------------|
| 1     | rt               | 5                   |
| 2     | 40               | 6                   |
| 3     | 50               | 15                  |
| 4     | 60               | 24                  |
| 5     | 70               | 47                  |
| 6     | 80               | 55                  |

<sup>a</sup>Conversion and yield were determined by <sup>1</sup>H NMR.

**Procedure for screening solvents (Table S3)** - Individual 4 mL vials were charged with cinnamyl azide (24.2-27.4 mg, 0.152-0.172 mmol, 1 equiv) and naphthalene (10.5-11.8 mg, 82.0-92.2  $\mu$ mol). Each respective solvent (0.8 mL, 0.2 M) was added followed by methyl acrylate (17  $\mu$ L, 0.19 mmol, 1.2 equiv) and TEA (66  $\mu$ L, 0.47 mmol, 3 equiv). The reactions were sealed under air and heated to 70  $^{\circ}$ C. After 24 h, the reactions were concentrated under reduced pressure and analyzed by  $^1$ H NMR.

**Table S3. Solvent Screen.**


| Entry | Solvent                                       | 1a (%) <sup>a</sup> | 5a (%) <sup>a</sup> | 3a (%) <sup>a</sup> | 4a (%) <sup>a</sup> |
|-------|---|---------------------|---------------------|---------------------|---------------------|
| 1     | MeOH  | 3                   | 3                   | 0                   | 38                  |
| 2     | DMSO  | -                   | 21                  | 0                   | 34                  |
| 3     | EtOAc   | 37                  | 37                  | 6                   | 6                   |
| 4     | Acetone                                       | 29                  | 38                  | 2                   | 13                  |
| 5     | DME   | 34                  | 38                  | 7                   | 8                   |
| 6     | Dioxane                                       | 34                  | 41                  | 12                  | 10                  |
| 7     | MTBE  | 48                  | 31                  | 7                   | 5                   |
| 8     | DCE   | 27                  | 21                  | 0                   | -                   |
| 9     | THF   | 24                  | 37                  | 4                   | 7                   |
| 10    | C <sub>6</sub> H <sub>6</sub>                 | 19                  | 45                  | 0                   | 9                   |
| 11    | PhMe  | 40                  | 50                  | 7                   | 8                   |
| 12    | C <sub>6</sub> H <sub>4</sub> Cl <sub>2</sub> | 29                  | 45                  | 1                   | 12                  |

<sup>a</sup>Conversion and yield were determined by  $^1$ H NMR.


**Table S4. Non-polar solvent screen.**

| entry | solvent         | 1d (%) <sup>a</sup> | 5d (%) <sup>a</sup> | 3d (%) <sup>a</sup> | 4d (%) <sup>a</sup> |
|-------|-----------------|---------------------|---------------------|---------------------|---------------------|
| 1     | Hexanes         | 18                  | 56                  | 1                   | 10                  |
| 2     | Pentanes        | 24                  | 52                  | 0                   | 25                  |
| 3     | Petroleum ether | 26                  | 53                  | 0                   | 22                  |


<sup>a</sup>Conversion and yield were determined by  $^1$ H NMR.

**Table S5. Acid additive screen.**

| entry | additive      | 1d (%) <sup>a</sup> | 5d (%) <sup>a</sup> | 3d (%) <sup>a</sup> | 4d (%) <sup>a</sup> |
|-------|---------------|---------------------|---------------------|---------------------|---------------------|
| 1     | None          | 1                   | 46                  | 17                  | 9                   |
| 2     | TFA (1.5 eq)  | 1                   | 21                  | 3                   | 29                  |
| 3     | TFA (2.5 eq)  | 1                   | 20                  | 2                   | 32                  |
| 4     | AcOH (1.5 eq) | 6                   | 9                   | 0                   | 56                  |
| 5     | AcOH (2.5 eq) | 4                   | 3                   | 0                   | 67                  |

<sup>a</sup>Conversion and yield were determined by <sup>1</sup>H NMR.**Table S6. Base and buffer additive screen.**






| entry | base            | acid | 5d (%) <sup>a</sup> | 3d (%) <sup>a</sup> | 4d (%) <sup>a</sup> |
|-------|-----------------|------|---------------------|---------------------|---------------------|
| 1     | TEA             | -    | 35                  | 4                   | 14                  |
| 2     | DIPEA           | -    | 13                  | 67                  | 0                   |
| 3     | pyridine        | -    | 14                  | 67                  | 0                   |
| 4     | DMAP            | -    | 36                  | 0                   | 25                  |
| 5     | N-methylaniline | -    | 10                  | 62                  | 0                   |
| 6     | TEA             | HCl  | 37                  | 4                   | 14                  |
| 7     | DIPEA           | HCl  | 22                  | 0                   | 36                  |
| 8     | DMAP            | HCl  | 32                  | 0                   | 27                  |


<sup>a</sup>Conversion and yield were determined by <sup>1</sup>H NMR.**Table S7. Equivalents of DIPEA screen.**

| entry | DIPEA (equiv) | 2d (%) <sup>a</sup> | 5d (%) <sup>a</sup> | 3d (%) <sup>a</sup> | 4d (%) <sup>a</sup> |
|-------|---------------|---------------------|---------------------|---------------------|---------------------|
| 1     | 3.0           | 0                   | 22                  | 58                  | 6                   |
| 2     | 1.5           | 0                   | 17                  | 65                  | 3                   |
| 3     | 1.0           | 0                   | 17                  | 65                  | 3                   |
| 4     | 0.5           | 0                   | 41                  | 23                  | 0                   |
| 5     | 0             | 41                  | 0                   | 42                  | 0                   |


<sup>a</sup>Conversion and yield were determined by <sup>1</sup>H NMR.

**Table S8 X-ray Data**


|   | <b>2hh</b>  | <b>5a</b>   | <b>5bb</b>   | <b>5v·HCl</b>   | <b>S1</b>   |
|---|---|---|--|---|---|
| structure                               |  |  |  |  |  |
| CCDC number                             | 1978783   | 1978781   | 1978782  | 1980239   | 1986830   |
| formula                                 | C <sub>24</sub> H <sub>20</sub> N <sub>4</sub> O <sub>3</sub>                     | C <sub>13</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub>                     | C <sub>14</sub> H <sub>16</sub> N <sub>4</sub> O <sub>4</sub>                      | C <sub>17</sub> H <sub>22</sub> ClN <sub>3</sub> O <sub>2</sub> ·1/2 HCl            | C <sub>38</sub> H <sub>33</sub> N <sub>3</sub> O <sub>2</sub>                       |
| formula weight                          | 412.1535  | 245.1164  | 304.1172   | 353.1285  | 563.2573  |
| crystal system                          | monoclinic  | orthorhombic  | monoclinic   | monoclinic  | monoclinic  |
| space group                             | <i>P</i> 2 <sub>1</sub> / <i>c</i>  | <i>P</i> 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>                             | <i>P</i> 2 <sub>1</sub> / <i>c</i>   | <i>P</i> 2 <sub>1</sub> / <i>c</i>  | <i>C</i> <sub>2</sub>   |
| a (Å)                                   | 29.875(10)  | 6.0964(2)   | 7.1080(4)  | 14.0598(19)   | 17.0760(16)   |
| b (Å)                                   | 5.607(2)  | 10.1676(3)  | 10.7667(6)   | 15.723(2)   | 9.7625(10)  |
| c (Å)                                   | 12.349(4)   | 19.2632(7)  | 18.9286(9)   | 32.139(4)   | 18.847(3)   |
| α (°)                                   | 90  | 90  | 90   | 90  | 90  |
| β (°)                                   | 101.081(13)   | 90  | 91.471(2)  | 91.764(5)   | 110.108(3)  |
| γ (°)                                   | 90  | 90  | 90   | 90  | 90  |
| V (Å <sup>3</sup> )                     | 2030.1(12)  | 1194.04(7)  | 1448.12(13)  | 7101.3(17)  | 2950.4(6)   |
| Z                                       | 4   | 4   | 4  | 4   | 4   |
| D <sub>calcd</sub> (g/cm <sup>3</sup> ) | 1.349   | 1.364   | 1.396  | 1.325   | 1.269   |
| temperature (K)                         | 100   | 100   | 125  | 125   | 126   |
| θ <sub>min</sub>                        | 2.78  | 2.91  | 2.18   | 2.67  | 2.30  |
| θ <sub>max</sub>                        | 30.40   | 30.41   | 30.52  | 27.60   | 26.07   |
| number of reflections                   | 6181  | 3562  | 4439   | 9879  | 7390  |
| R1                                      | 0.0573  | 0.0384  | 0.0395   | 0.0403  | 0.0543  |
| wR2                                     | 0.1475  | 0.1073  | 0.1503   | 0.1145  | 0.1518  |
| sample preparation                      | slow evaporation with DCM   | slow diffusion using DCM/hexanes  | slow diffusion using DCM/hexanes   | slow diffusion using HCl in dioxane/toluene   | slow diffusion using DCM/hexanes  |




**Figure S1.** ORTEP drawing of compound **2hh** showing thermal ellipsoids at the 50% probability level




**Figure S2.** ORTEP drawing of compound **5a** showing thermal ellipsoids at the 50% probability level



**Figure S3.** ORTEP drawing of compound **5bb** showing thermal ellipsoids at the 50% probability level



**Figure S4.** ORTEP drawing of compound **5v·HCl** showing thermal ellipsoids at the 50% probability level (omit hydrogens for clarity)



**Figure S5.** ORTEP drawing of compound **S1** showing thermal ellipsoids at the 50% probability level

## HPLC data

General: Enantiomeric ratios were determined using a Shimadzu HPLC with a PDA detector and a RegisPack 5 Micron column or Regis Reflect column (C-Amylose A; 3 $\mu$ , 250 mm x 4.6 mm). The purification of enantioenriched azide **1v** was adapted from a known method using a semi-preparative chiral HPLC.<sup>1</sup> The absolute configuration of enantioenriched azide **1v** was assigned arbitrarily. Each enantioenriched azide **1v** was converted to the corresponding bicyclic amine **5v**. The yield and er were determined individually and the average value were reported as duplicate trials. Each sample was injected in duplicate. For each sample, the racemic retention time standard was run before and after the sample (4 total injections per sample).

## HPLC Images

Compound **1v**: RegisPack 5 Micron, hexane : *i*PrOH = 98.8: 0.2 at 1.5 mL/min, T = 40 °C,  $\lambda$  = 249 nm:  $t_{ent1}$  = 5.4 min,  $t_{ent2}$  = 6.4 min

Figure S6. HPLC trace




Table S9. Tabulated Areas

| Peak# | Ret. Time | Area    | Area% |
|-------|-----------|---------|-------|
| 1     | 5.4       | 4931906 | 50.0  |
| 2     | 6.4       | 4939090 | 50.0  |
| Total |           | 9870996 | 100.0 |

Figure S7. HPLC trace





Table S10. Tabulated Areas

| Peak# | Ret. Time | Area    | Area% |
|-------|-----------|---------|-------|
| 1     | 5.4       | 8421249 | 99.5  |
| 2     | 6.4       | 43427   | 0.5   |
| Total |           | 8464676 | 100.0 |



**Figure S8.** HPLC trace




**Table S11.** Tabulated Areas

| Peak# | Ret. Time | Area     | Area% |
|-------|-----------|----------|-------|
| 1     | 5.4       | 4844     | 0.0   |
| 2     | 6.4       | 11253374 | 100.0 |
| Total |           | 11258217 | 100.0 |

Compound **5v**: Reflect, C-Amylose A, hexane : *i*PrOH = 85: 15 at 1.0 mL/min, T = 40 °C,  $\lambda$  = 215 nm;  $t_{\text{ent}1}$  = 10.6 min,  $t_{\text{ent}2}$  = 12.7 min


**Figure S9.** HPLC trace



**Table S12.** Tabulated Areas

| Peak# | Ret. Time | Area    | Area% |
|-------|-----------|---------|-------|
| 1     | 10.6      | 1410043 | 50.1  |
| 2     | 12.7      | 1402667 | 49.9  |
| Total |           | 2812709 | 100.0 |


**Figure S10.** HPLC trace



**Table S13.** Tabulated Areas

| Peak# | Ret. Time | Area    | Area% |
|-------|-----------|---------|-------|
| 1     | 10.7      | 7234990 | 100   |
| Total |           | 7234990 | 100   |

**Figure S11.** HPLC trace




**Table S14.** Tabulated Areas

| Peak# | Ret. Time | Area    | Area% |
|-------|-----------|---------|-------|
| 1     | 10.9      | 6973    | 0.3   |
| 2     | 12.8      | 2757567 | 99.7  |
| Total |           | 2764540 | 100.0 |


## References

- (1) Ott, A. A.; Packard, M. H.; Ortuño, M. A.; Johnson, A.; Suding, V. P.; Cramer, C. J.; Topczewski, J. J. Evidence for a Sigmatropic and an Ionic Pathway in the Winstein Rearrangement. *J. Org. Chem.* **2018**, *83*, 8214–8224.


## NMR Spectra Images





Compound **1b**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$





**1b**




Compound **1b**. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>



Compound **1i**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




Compound **1i**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




**1i**

-59.43




Compound **1i**. 101 MHz  $^{19}\text{F}$  NMR spectrum in  $\text{CDCl}_3$




Compound **11**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>







**11**




Compound **11**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **1m**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




**1m**




Compound **1m**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **1n**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$





**1n**




Compound **1n**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **1s'**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>



Compound **1s'**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




-62.83




Compound **1s'**. 376 MHz  $^{19}\text{F}$  NMR spectrum in  $\text{CDCl}_3$







Compound **1s''**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **1s''**. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




-62.90




Compound **1s''**. 376 MHz  $^{19}\text{F}$  NMR spectrum in  $\text{CDCl}_3$



Compound **1s**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **1s**. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




**1s**


---62.90



Compound **1s**. 376 MHz <sup>19</sup>F NMR spectrum in CDCl<sub>3</sub>




Compound **2hh**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **2hh**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_3\text{CN}$







5a




Compound 5a. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




5a



Compound 5a. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>



Compound **5b**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>



**5b**


—173.54

149.09  
149.03


132.17  
129.68  
129.37  
126.20  
124.06

—81.24


61.39  
60.02  
53.88  
52.87




Compound **5b**. 101 MHz <sup>13</sup>C NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>





Compound **5c**. 500 MHz <sup>1</sup>H NMR spectrum in C<sub>6</sub>D<sub>6</sub>



Compound **5c**. 126 MHz <sup>13</sup>C NMR spectrum in C<sub>6</sub>D<sub>6</sub>




Compound **5d**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{C}_6\text{D}_6$




Compound **5d**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$







Compound **5e**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{C}_6\text{D}_6$




Compound **5e**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{C}_6\text{D}_6$




Compound **5f**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{C}_6\text{D}_6$




Compound **5f**. 101 MHz <sup>13</sup>C NMR spectrum in C<sub>6</sub>D<sub>6</sub>




-62.72




Compound **5f**. 471 MHz  $^{19}\text{F}$  NMR spectrum in  $\text{CDCl}_3$



Compound **5g**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>




Compound **5g**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




Compound **5h**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{C}_6\text{D}_6$






Compound **5h**. 126 MHz <sup>13</sup>C NMR spectrum in C<sub>6</sub>D<sub>6</sub>







Compound **5i**. 101 MHz <sup>13</sup>C NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>




**5i**




Compound **5i**. 376 MHz  $^{19}\text{F}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$





Compound **5j**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>3</sub>CN



Compound **5j**. 101 MHz <sup>13</sup>C NMR spectrum in CD<sub>3</sub>CN




Compound **5k**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




Compound **5k**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$







Compound **5l**. 500 MHz <sup>1</sup>H NMR spectrum in C<sub>6</sub>D<sub>6</sub>




Compound **5I**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{C}_6\text{D}_6$





Compound **5m**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>





Compound **5m**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$





Compound **5n**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>



Compound **5n**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




Compound **5o**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5o**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$







Compound **5p**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **5p**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5q**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CD}_3\text{CN}$




Compound **5q**. 101 MHz <sup>13</sup>C NMR spectrum in CD<sub>3</sub>CN




Compound **5r**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




**5r**



Compound **5r**. 101 MHz <sup>13</sup>C NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>




Compound **5s**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **5s**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$







-62.85




Compound **5s**. 376 MHz  $^{19}\text{F}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5s**. COSY NMR spectrum in CDCl<sub>3</sub>





Compound **5s**. COSY NMR spectrum in CDCl<sub>3</sub> (expansion)





Compound **5s**. NOESY spectrum in CDCl<sub>3</sub>




Compound **5s**. NOESY spectrum in CDCl<sub>3</sub> (expansion)



Compound **5t**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$





Compound **5t**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




Compound **5u**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>








Compound **5u**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




Compound **5v**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>3</sub>CN



Compound **5v**. 101 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CD}_3\text{CN}$




Compound **5w**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




**5w**


E = CO<sub>2</sub>Et




Compound **5w**. 126 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>



Compound **5x**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$





Compound **5x**. 126 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




Compound **5y**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>








Compound **5y**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5z**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5z**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5aa**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **5aa**. 126 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




Compound **5bb**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>



**5bb**




Compound **5bb**. 126 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




Compound **5cc**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$






**5cc**



Compound **5cc**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$



Compound **4dd**. 400 MHz  $^1\text{H NMR}$  spectrum in  $\text{CDCl}_3$

207.35  
206.24

149.57  
148.08



133.01  
131.21  
129.69  
127.17  
124.49

82.24


64.31  
57.59  
56.34

49.02  
42.66

29.91  
25.29



Compound **4dd**. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>



Compound **5dd**. 400 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>



—204.95

148.39  
147.77  
144.48  
133.72  
131.84  
131.45  
130.26  
129.94  
127.96  
126.68  
124.79


—81.71

57.34  
56.69  
51.29

—25.55  
—21.61




Compound **5dd**. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




7.78  
7.77  
7.66  
7.66  
7.62  
7.55  
7.54  
7.53  
7.52  
7.52  
7.41

4.03  
4.02  
3.13  
3.11  
3.05  
3.04  
3.02  
3.01  
3.00  
2.89  
2.87  
2.28



Compound **5ee**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{DMSO-}d_6$




— 175.43

— 149.06  
— 145.83


— 132.42  
— 129.90  
— 129.39  
— 125.53  
— 124.07

— 79.85

— 61.24  
— 59.82  
— 54.22




Compound **5ee**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{DMSO-}d_6$



Compound **5ff**. 500 MHz <sup>1</sup>H NMR spectrum in DMSO-*d*<sub>6</sub>







148.93  
146.46

132.71  
130.25  
130.10  
124.71  
124.29  
120.83



67.66  
61.73  
61.42  
53.47



Compound **5ff**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{DMSO-}d_6$





Compound **5gg**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




Compound **5gg**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$


— 23.27




Compound **5gg**. 162 MHz  $^{31}\text{P}$  NMR spectrum in  $\text{CDCl}_3$




Compound **9a**. 400 MHz <sup>1</sup>H NMR spectrum in CD<sub>3</sub>CN



Compound **9a**. 100 MHz <sup>13</sup>C NMR spectrum in CD<sub>3</sub>CN




Compound **9b**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




Compound **9b**. 100 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$







Compound **9c**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **9c**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$




Compound **9d**. 400 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




Compound **9d**. 101 MHz <sup>13</sup>C NMR spectrum in CDCl<sub>3</sub>




**10**




Compound **10**. 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CD}_2\text{Cl}_2$




**10**




Compound **10**. 126 MHz <sup>13</sup>C NMR spectrum in CD<sub>2</sub>Cl<sub>2</sub>




**11**



Compound **11**: 500 MHz  $^1\text{H}$  NMR spectrum in  $\text{CDCl}_3$




11




Compound 11: 126 MHz <sup>13</sup>C NMR spectrum in MeOD








Compound **12**. 500 MHz <sup>1</sup>H NMR spectrum in MeOD:TFA (50:1)



Compound **12**. 126 MHz  $^{13}\text{C}$  NMR spectrum in MeOD:TFA (50:1)




Compound **13**: 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>




Compound **13**: 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$







Compound **15**. 500 MHz <sup>1</sup>H NMR spectrum in CDCl<sub>3</sub>



Compound **15**. 126 MHz  $^{13}\text{C}$  NMR spectrum in  $\text{CDCl}_3$